中证智能财讯 惠泰医疗（688617）2月10日公告，基于对公司未来发展前景的信心及长期投资价值的认 可，为增强投资者信心并建立健全长效激励机制，公司计划以自有资金通过集中竞价交易方式回购部分 股份，回购资金总额不低于1.5亿元且不超过2亿元，回购价格上限为315元/股，回购期限为董事会审议 通过之日起10个月内。本次回购股份将在未来适宜时机用于员工持股计划或股权激励。公司股票2月9日 收盘价为229.38元/股。 2025年前三季度，公司实现营业总收入18.67亿元，同比增长22.47%；归母净利润6.23亿元，同比增长 18.02%。 核校：孙萍 按回购价格上限测算，预计回购股份数量为47.62万股至63.49万股，占公司总股本的0.34%至0.45%。公 司表示，本次回购不会对公司的日常经营、财务、研发和未来发展产生重大影响，公司有能力支付回购 价款。若回购股份未能在三年内转让完毕，将依法予以注销。 惠泰医疗是一家专注于电生理和介入类医疗器械的研发、生产和销售的高新技术企业，已形成了以完整 冠脉通路和心脏电生理医疗器械为主导，外周血管和非血管介入医疗器械为重点发展方向的业务布局。 ...

Group 1 - The core point of the article is the significant share reduction by the vice chairman and general manager of Huitai Medical, Cheng Zhenghui, who sold 2% of his shares at a price significantly lower than the market price, with the buyer being Shenzhen Mindray Technology, the controlling shareholder of Huitai Medical [1][2][5] - Cheng Zhenghui reduced his holdings from 25,373,507 shares to 23,551,232 shares, lowering his ownership percentage to 16.70% [2][5] - The share reduction occurred between September 3 and September 11, 2025, at a price of 248.20 yuan per share, totaling nearly 700 million yuan, while the market price was above 300 yuan during that period [2][5][10] Group 2 - Shenzhen Mindray Technology increased its stake in Huitai Medical by acquiring 2,164,739 shares on September 11, 2025, raising its total holdings from 35,253,449 shares to 37,418,188 shares, resulting in a new ownership percentage of 26.54% [5][9] - Huitai Medical has shown impressive growth, with revenue increasing from 479 million yuan in 2020 to 2.066 billion yuan in 2024, and net profit rising from 111 million yuan to 673 million yuan during the same period [9][10] - In the first half of 2025, Huitai Medical reported revenue of 1.214 billion yuan, a year-on-year increase of 21.26%, and net profit of 425 million yuan, up 24.11% [10]